Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson's Progression Markers Initiative.
Barbosa W, Schneider RB, Choi SH, Marshall MJ, Lafontant DE, Caspell-Garcia C, Coffey CS, Ross J, Siderowf A, Marek K, Simuni T; Parkinson’s Progression Markers Initiative (PPMI). Barbosa W, et al. Among authors: simuni t. Clin Park Relat Disord. 2025 Aug 13;13:100385. doi: 10.1016/j.prdoa.2025.100385. eCollection 2025. Clin Park Relat Disord. 2025. PMID: 40895170 Free PMC article.
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study.
Hoyt A, Dorney C, Auinger P, Murphy K, Porto M, Schmier K, Wilson R, Beck JC, Benvengo S, Biglan K, Dorsey ER, Espay AJ, Macklin EA, Monje MH, Novak D, Oakes D, Omberg L, Schwarzschild MA, Sieberts SK, Simuni T, Tanner CM, Weintraub D, Schneider RB. Hoyt A, et al. Among authors: simuni t. JMIR Res Protoc. 2025 Aug 27;14:e71955. doi: 10.2196/71955. JMIR Res Protoc. 2025. PMID: 40864497 Free PMC article.
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: simuni t. NPJ Parkinsons Dis. 2025 Aug 13;11(1):241. doi: 10.1038/s41531-025-01103-y. NPJ Parkinsons Dis. 2025. PMID: 40804248 Free PMC article. No abstract available.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.
Iwatsubo T, Sperling RA, Algeciras-Schimnich A, Arai H, Barron AM, Benzinger TLS, Carrillo MC, Chen C, Choi SH, Fontana IC, Graff-Radford J, Grill JD, Heidebrink J, Hu CJ, Ihara R, Ikeuchi T, Iwata A, Ip FCF, Fitri FI, Jack CR Jr, Jeong JH, Jia J, Kandiah N, Kim S, Kowa H, La Joie R, Niimi Y, Noritake R, Okonkwo OC, Palmqvist S, Rafii MS, Raman R, Shen Y, Simuni T, Snyder HM, Sriwannopas O, Stoeckel LE, van der Flier WM, Wang H, Wilcock DM, Zetterberg H, Zhou J, Mahinrad S, Sexton CE. Iwatsubo T, et al. Among authors: simuni t. Alzheimers Dement. 2025 Aug;21(8):e70536. doi: 10.1002/alz.70536. Alzheimers Dement. 2025. PMID: 40760693 Free PMC article. Review.
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder.
Weintraub D, Nair AR, Kurth R, Brumm MC, Kohnen C, York MK, Dobkin RD, Marek K, Tanner C, Simuni T, Siderowf A, Galasko D, Chahine LM, Coffey C, Merchant K, Poston KL, Foroud T, Mollenhauer B, Brown EG, Kieburtz K, Frasier M, Chowdhury S, Alcalay RN, Videnovic A; Parkinson's Progression Markers Initiative. Weintraub D, et al. Among authors: simuni t. Ann Neurol. 2025 Sep;98(3):482-491. doi: 10.1002/ana.27263. Epub 2025 Jul 11. Ann Neurol. 2025. PMID: 40641332 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: simuni t. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
279 results